Publications by authors named "L C Musib"
Background: High-dimensional omics data integration has emerged as a prominent avenue within the healthcare industry, presenting substantial potential to improve predictive models. However, the data integration process faces several challenges, including data heterogeneity, priority sequence in which data blocks are prioritized for rendering predictive information contained in multiple blocks, assessing the flow of information from one omics level to the other and multicollinearity.
Methods: We propose the Priority-Elastic net algorithm, a hierarchical regression method extending Priority-Lasso for the binary logistic regression model by incorporating a priority order for blocks of variables while fitting Elastic-net models sequentially for each block.
Giredestrant is a potent and selective small-molecule estrogen receptor degrader. The objectives of this study were to assess the absolute bioavailability (aBA) of giredestrant and to determine the mass balance, routes of elimination, and metabolite profile of [C]giredestrant. In part 1 (mass balance), a single 30.
View Article and Find Full Text PDFArticle Synopsis
- Ipatasertib (GDC-0068) is a targeted cancer treatment being developed by Genentech/Roche, focusing on inhibiting the Akt protein kinase, with studies examining its effects both alone and with other therapies.
- An open-label study with radiolabeled ipatasertib assessed how the drug is absorbed, metabolized, and excreted, showing a bioavailability of 34.0% and similar terminal half-lives for oral and intravenous forms.
- The majority of the drug recovered was metabolized, primarily through hepatic pathways, with the main metabolic process being -dealkylation facilitated by the CYP3A enzyme.
Article Synopsis
- The MAPK pathway is being targeted in various tumors, and MEK1 inhibitors like cobimetinib are proposed to manage MAPK-dependent cancers in young patients.
- The iMATRIX-cobi study evaluated the safety and anti-tumor effects of cobimetinib in children and young adults aged 6 months to 30 years with solid tumors linked to the MAPK pathway.
- The results showed that while the safety profile for cobimetinib was similar to adults, only a few patients (5.4%) experienced partial tumor responses, indicating the need for further combination treatments to enhance effectiveness.
Purpose: Ipatasertib, a potent and highly selective small-molecule inhibitor of AKT, is currently under investigation for treatment of cancer. Ipatasertib is a substrate and a time-dependent inhibitor of CYP3A4. It exhibits non-linear pharmacokinetics at subclinical doses in the clinical dose escalation study.
View Article and Find Full Text PDF